Document 0250
 DOCN  M9440250
 TI    Provirus load changes in untreated and zidovudine-treated human
       immunodeficiency virus type 1-infected patients.
 DT    9404
 AU    Luque F; Caruz A; Pineda JA; Torres Y; Larder B; Leal M; Department of
       Biochemistry and Internal Medicine, Virgen del; Rocio Universitary
       Hospital, Seville, Spain.
 SO    J Infect Dis. 1994 Feb;169(2):267-73. Unique Identifier : AIDSLINE
       MED/94149309
 AB    Human immunodeficiency virus type 1 (HIV-1) provirus burden was
       quantified during follow-up of untreated patients and mathematically
       analyzed by a parameter called intrinsic rate of increase (r). There was
       an increase in provirus burden in patients at early stages of the
       infection, and the increase occurred at a similar rate in later stages
       of the disease. Antiviral response to zidovudine was evaluated using r.
       Nearly 50% of patients responded with strong decreases of r, and the
       rest behaved as nonresponders. Parameter r is valuable in disease
       prognosis, as the mean r was higher in disease progressors than in
       nonprogressors, and this difference was significant and more pronounced
       in treated patients. The zidovudine resistance mutation at codon 215 of
       reverse transcriptase was associated with a worse response to therapy.
       Absence of antiviral response and resistance mutations were more
       frequent in patients with lower CD4+ cell counts and higher provirus
       loads. These findings support a more beneficial effect of early than
       late therapy.
 DE    DNA, Viral/ANALYSIS  Human  HIV Infections/*DRUG
       THERAPY/IMMUNOLOGY/MICROBIOLOGY  HIV-1/CLASSIFICATION/GROWTH &
       DEVELOPMENT  Leukocyte Count  *Proviruses  Time Factors  T4 Lymphocytes
       Zidovudine/*THERAPEUTIC USE  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).